Procter & Gamble and Sanofi-Aventis seek stop to Boniva ads

Share this article:
Procter & Gamble and Sanofi-Aventis filed a lawsuit in Manhattan federal court Wednesday seeking an injunction to halt advertising for Roche and GlaxoSmithKline’s jointly marketed Boniva (ibandronate sodium). The lawsuit alleges the professional and consumer ads for Boniva falsely claim the drug has been proven to be more effective than Actonel (risedronate sodium tablets), jointly marketed by Procter & Gamble and Sanofi-Aventis. “The medications have not been compared in head-to-head clinical studies.” Procter & Gamble and Sanofi-Aventis said in a joint news release. “However, Boniva has not been proven to reduce the risk of nonspinal fracture.  In its pivotal clinical trial, there were a similar number of nonspinal osteoporotic fractures at 3 years in women treated with Boniva and placebo.” A spokeswoman for Roche in an Associated Press report that the firm “is confident the advertising accurately and appropriately reflects the clinical findings.” A spokeswoman for GlaxoSmithKline added in the published report that the company had yet to see the lawsuit but believed that its Boniva advertising “has been truthful and accurate.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...